Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 309 clinical trials
featured
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US  

(diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central nervous system

  • 2173 views
  • 30 Aug, 2021
  • 16 locations
featured
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US Spanish  

(diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central nervous system

  • 301 views
  • 26 Mar, 2021
  • 16 locations
featured
A safety and Tolerability Study of INCB053915 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

The purpose of this study is to evaluate the safety and tolerability of INCB053914 in combination with INCB050465 in relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).  

lymphoma
b-cell lymphoma
lymphomas
  • 45 views
  • 25 Aug, 2021
  • 3 locations
featured
A Study of INCB039110 in Combination With Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Study of INCB039110 in Combination With Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  • 180 views
  • 25 Mar, 2021
  • 1 location
Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis

large B-cell lymphoma (DLBCL).

da-epoch
chemoimmunotherapy
large cell lymphoma
follicular lymphoma
t-cell lymphoma
  • 32 views
  • 23 Jan, 2021
  • 18 locations
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer.

This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and expansion study including an intra-participant ramp-up. AZD4573 will be administered intravenously, in novel combinations with anti-cancer agents, to participants with relapsed/refractory haematological malignancies.

  • 0 views
  • 17 Sep, 2021
  • 33 locations
Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)

chemotherapy (C2), on the probability of obtaining a metabolic complete response after 4 cycles of induction chemotherapy (C4) in patients with primary mediastinal large B cell lymphoma (PMBL) receiving

  • 0 views
  • 09 Apr, 2021
  • 2 locations
Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma

This is an open-label, multicenter, dose-escalation phase 1 study to determine the Safety and Efficacy of BZ019 in relapsed or refractory CD19+ B-cell Lymphoma subjects.

  • 0 views
  • 23 Jan, 2021
  • 2 locations
Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma

with relapsed or refractory chemosensitive diffuse large B-cell lymphoma

cancer chemotherapy
b-cell lymphoma
lenalidomide
high dose chemotherapy
rituximab
  • 28 views
  • 07 Nov, 2020
  • 1 location
CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

The primary objective of this study is to explore the safety and efficacy of CNCT19 (a second-generation anti-CD19 CAR T-cell using 4-1BB as co-stimulatory domain provided by Juventas, Tianjin, China) infusion following ASCT in patients with relapsed or refractory B-cell lymphoma.

  • 0 views
  • 27 Jan, 2021
  • 1 location